Eva Havrdova Selected Research

daclizumab HYP

10/2015	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
5/2014	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
4/2014	Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
2/2014	Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis.
6/2013	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eva Havrdova Research Topics

Disease

56	Multiple Sclerosis 04/2021 - 09/2005
40	Relapsing-Remitting Multiple Sclerosis 01/2022 - 05/2007
10	Atrophy 01/2018 - 07/2011
7	Disease Progression 09/2014 - 04/2010
6	Infections 10/2019 - 02/2012
4	Flushing 09/2015 - 10/2008
3	Chronic Progressive Multiple Sclerosis 01/2021 - 01/2017
3	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2017 - 11/2012
2	Papillary Carcinoma 01/2017 - 11/2012
2	Neoplasms (Cancer) 01/2017 - 12/2012
2	Exanthema (Rash) 10/2015 - 06/2013
2	Progressive Multifocal Leukoencephalopathy 02/2012 - 09/2007
2	Fatigue 10/2008 - 03/2006
1	Lymphopenia (Lymphocytopenia) 01/2018
1	Melanoma (Melanoma, Malignant) 01/2017
1	Congenital Heart Defects (Congenital Heart Defect) 12/2016
1	Spontaneous Abortion (Miscarriage) 12/2016
1	Transposition of Great Vessels (Great Vessels Transposition) 12/2016
1	Ulcerative Colitis 07/2016
1	Pneumonia (Pneumonitis) 07/2016
1	Urinary Tract Infections (Urinary Tract Infection) 07/2016
1	Optic Neuritis (Retrobulbar Neuritis) 05/2016
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2015
1	Normal Pressure Hydrocephalus 12/2015
1	Eczema 10/2015
1	Inflammation (Inflammations) 10/2015
1	Frailty 08/2015
1	Nervous System Diseases (Neurological Disorders) 09/2014
1	Neuromyelitis Optica (Devic's Disease) 09/2014
1	Autoimmune Hepatitis 05/2014
1	Psoas Abscess 06/2013
1	Rheumatoid Arthritis 04/2010
1	Abdominal Pain (Pain, Abdominal) 10/2008
1	Headache (Headaches) 10/2008
1	Opportunistic Infections (Opportunistic Infection) 05/2007
1	Hypersensitivity (Allergy) 03/2006

Drug/Important Bio-Agent (IBA)

15	Interferon beta-1a FDA Link 10/2019 - 10/2007
14	Dimethyl FumarateIBA 01/2022 - 10/2008
13	Natalizumab (Tysabri)FDA Link 01/2022 - 03/2006
10	Glatiramer Acetate (Copaxone)FDA Link 01/2022 - 04/2010
10	Alemtuzumab (Campath)FDA Link 10/2019 - 11/2012
10	Interferon-betaIBA 01/2017 - 07/2007
9	Fingolimod Hydrochloride (FTY720)FDA Link 01/2022 - 05/2012
9	InterferonsIBA 01/2022 - 09/2012
6	Biomarkers (Surrogate Marker)IBA 01/2018 - 08/2014
5	Daclizumab (Zenapax)FDA Link 11/2017 - 06/2013
5	daclizumab HYPIBA 10/2015 - 06/2013
4	CholesterolIBA 01/2017 - 10/2013
4	Monoclonal AntibodiesIBA 01/2015 - 11/2012
3	Pharmaceutical PreparationsIBA 01/2018 - 09/2007
3	AntibodiesIBA 09/2014 - 07/2007
2	Cytidine Diphosphate (CDP)IBA 01/2018 - 11/2016
2	LipidsIBA 01/2017 - 11/2013
2	SteroidsIBA 11/2015 - 09/2005
2	ApolipoproteinsIBA 10/2015 - 08/2014
2	Immunologic Factors (Immunomodulators)IBA 08/2015 - 02/2012
2	FumaratesIBA 03/2015 - 10/2008
2	oxidized low density lipoproteinIBA 11/2013 - 10/2013
1	teriflunomideIBA 01/2022
1	Acyclovir (Aciclovir)FDA LinkGeneric 10/2019
1	Cladribine FDA LinkGeneric 10/2018
1	ChitinasesIBA 01/2018
1	Oligoclonal BandsIBA 01/2018
1	Staphylococcal Protein A (Protein A)IBA 01/2017
1	Neutralizing AntibodiesIBA 01/2017
1	Messenger RNA (mRNA)IBA 01/2017
1	Lisinopril (Prinivil)FDA LinkGeneric 12/2016
1	EnzymesIBA 07/2016
1	Retinaldehyde (Retinal)IBA 05/2016
1	AlbuminsIBA 01/2016
1	CytokinesIBA 12/2015
1	Transaminases (Aminotransferases)IBA 10/2015
1	Interleukin-2 (IL2)IBA 10/2015
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 09/2014
1	Complement System Proteins (Complement)IBA 09/2014
1	Vitamin D FDA LinkGeneric 09/2014
1	Apolipoproteins E (ApoE)IBA 08/2014
1	lipoprotein cholesterolIBA 08/2014
1	Apolipoproteins B (ApoB)IBA 08/2014
1	GadoliniumIBA 04/2014
1	ofatumumab FDA Link 02/2014
1	GoldIBA 10/2013
1	Azathioprine (Imuran)FDA LinkGeneric 12/2012
1	HLA-DRB1 Chains (HLA DRB1)IBA 07/2011
1	Biological ProductsIBA 04/2010
1	Cytostatic AgentsIBA 09/2005

Therapy/Procedure

33	Therapeutics 01/2022 - 10/2005
3	Injections 08/2015 - 03/2015
2	Immunotherapy 06/2017 - 01/2017
2	Immunomodulation 03/2017 - 04/2016
1	Retreatment 10/2019
1	Hematopoietic Stem Cell Transplantation 04/2017
1	Aftercare (After-Treatment) 01/2016
1	Subcutaneous Injections 06/2013
1	Stem Cell Transplantation 09/2005